November 05, 2026

National Stock Exchange of India Limited,
Compliance Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051,
Maharashtra, India

BSE Limited,
Compliance Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400001,
Maharashtra, India

Dear Sir/Madam,

Subject : ***Press Release on Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and six months ended September 30, 2026***

Stock Code : ***BSE – 539787, NSE – HCG***

Reference : ***Regulation 30, 33 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations")***

This is to inform you that the Board of Directors of the Company, at their meeting held today i.e., November 05, 2026, inter alia, has considered and approved the Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and six months ended September 30, 2026 ("Unaudited Financial Results").

We enclose herewith the communication being released to the Press on the Unaudited Financial Results of the Company.

The above information is also available on the website of the Company and can be accessed at: https://www.hcgoncology.com/investor-relations/

You are requested to take the intimation on record.

Thanking you,

For **HealthCare Global Enterprises Limited**

SUNU MANUEL ABEY
Digitally signed by SUNU MANUEL ABEY
Date: 2026.11.05 20:25:58 +05'30'

Sunu Manuel
Company Secretary & Compliance Officer

Encl: a/a

HCG Reports Q2 FY2027 Results, with Revenue up by 16% YoY and Adjusted EBITDA up by 17% YoY

Bangalore, 5th November 2026: Healthcare Global Enterprises Limited (HCG), India's largest dedicated cancer hospital network, under the brand "HCG", has announced its financial results for the quarter and half year ended 30th September 2026.

RESULTS HIGHLIGHTS (Consolidated)

Particulars (Rs. Mn.)	Q2FY27	Q2FY26	YoY	H1FY27	H1FY26	YoY
Revenue from Operations	7,318	6,321	**15.8%**	14,100	12,303	**14.6%**
Adjusted EBITDA[1]	1,425	1,215	**17.2%**	2,740	2,316	**18.3%**
Margin (%)	*19.7*	*19.2*	***+51 bps***	*19.7*	*18.8*	***+84 bps***
PBT before extraordinary items[2]	301	203	**48.1%**	553	328	**68.4%**
Adjusted Profit after Tax[3]	192	212	**-9.3%**	358	277	**29.2%**

(1) Adjusted EBITDA excludes North Bangalore Loss of INR 61 Mn in Q2'27 (INR 131 Mn in H1'27), ESOP cost of INR 29.8 Mn in Q2 '27 and EPCG-related provision of INR 45.9 Mn in H1'27; and ESOP of INR 14.3 Mn and M&A-related costs of INR 25.6 Mn in H1'26

(2) PBT before extraordinary item of INR 116 Mn

(3) Adjusted PAT normalized for extraordinary items of INR 116 Mn (INR 99 Mn post-tax). The YoY decline primarily reflects a favourable one-time deferred tax adjustment in Q2 FY26 against brought-forward losses and unabsorbed depreciation at Baroda

(4) All the above figures exclude the fertility business, following its divestment effective 30 June 2026

Dr. B. S. Ajaikumar, Founder and Non-Executive Chairman, HealthCare Global Enterprises Ltd., said

"At HCG, our focus remains firmly on advancing oncology care through clinical excellence, innovation, research and a deeply patient-centric approach. We believe the future of cancer care lies in bringing together advanced medical technologies, specialised clinical expertise and cutting-edge research to make treatment increasingly precise, personalised and effective.

We are strengthening our research capabilities across emerging areas such as multi-omics, organoid technology, cellular therapies including CAR-T, and longevity research, with a strong emphasis on translating scientific discoveries into meaningful clinical applications. Our endeavour is to bridge the gap between research and clinical practice, enabling us to better understand the biology of cancer, develop innovative treatment approaches and continually improve patient outcomes.

As we expand our network and enhance access to high-quality oncology services across geographies, our ambition is to build an institution that not only delivers excellence in cancer care today but also helps shape the future of medicine. We remain committed to advancing medical science, improving patient outcomes and creating sustainable long-term value for all our stakeholders."

Commenting on the results, Dr. Manish Mattoo, CEO, HealthCare Global Enterprises Ltd. said,

"We sustained our growth momentum in Q2 FY27, delivering revenue growth of 16% year-on-year to INR 7,318 million, driven by a 9% increase in patient volumes and a 7% improvement in average revenue per patient (ARPP). Adjusted EBITDA grew 17% year-on-year to INR 1,425 million, with a margin of 19.7%.

This performance reflects our continued focus on improving revenue mix, increasing the contribution from high-complexity oncology treatments and driving operational efficiencies. Our strategic emphasis on expanding the non-institutional business continues to enhance the quality of revenue, with its share improving by 325 basis points year-on-year to 69%.

Looking ahead, our priorities remain focused on improving asset utilisation, accelerating the ramp-up of newer facilities, enhancing productivity across our existing network and executing strategic capacity expansions. We remain committed to delivering sustainable, profitable growth while broadening access to advanced, high-quality cancer care."

Consolidated Highlights for the Quarter Ending 30th September, 26:

- HCG reported revenue of INR 7,318 Mn in Q2 FY27, representing 16% YoY growth, supported by broad-based growth across clusters
- Patient volumes increased by 9% YoY, while ARPP grew by 7%, driven by a favourable payor mix and higher contribution from advanced oncology treatments, including robotic surgeries (up 37% YoY) and other high-end therapies
- Adjusted EBITDA increased by 17% YoY to INR 1,425 Mn in Q2 FY27, with EBITDA margin improving to 19.7%, compared to 19.2% in Q2 FY26
- International business revenue grew by approximately 54% YoY to INR 302 Mn in Q2 FY27, driven by increased patient volumes in radiation and medical oncology

Key Business Developments for the Quarter Ending 30th September, 26:

- **Capacity Expansion:** Added 25 operational beds in Q2 FY27, comprising 13 beds in Kenya, 7 in Kolkata and 5 in Nagpur, taking total bed additions to 146 in H1 FY27
- **Advanced Technology Deployment:** Operationalised the state-of-the-art adaptive radiation therapy system MR-LINAC at North Bengaluru, a LINAC in Africa and a cardiac robotic surgery system at HMS Ahmedabad
- **Key Clinical Program Additions:**
    - **Advanced Cancer Therapies:** Performed first CAR-T cell therapy at HCC Ahmedabad, strengthening advanced oncology treatment capabilities
    - **Robotic & Minimally Invasive Surgery:** Introduced robotic breast surgery at KR, robotic spine surgery at Rajkot and Transoral Robotic Surgery (TORS) at Baroda
    - **Precision Diagnostics:** Launched a 1,212-gene liquid biopsy panel and introduced two new nuclear medicine tracers at KR, enhancing precision cancer diagnostics

***

About Healthcare Global Enterprises Limited (HCG):

HealthCare Global Enterprises Ltd. (HCG), headquartered in Bengaluru, is the largest provider of cancer care in India. Through its network of 26 hospitals across India and Africa, HCG has brought advanced cancer care to the doorstep of millions of people. HCG's comprehensive cancer centers provide expertise and advanced technologies for the effective diagnosis and treatment of cancer under one roof.

For updates and specific queries, please visit www.hcgel.com or feel free to contact

Healthcare Global Enterprises Limited	**CDR India**
Ravi Gothwal - Head Investor Relations	Anoop Poojari / Suraj Digawalekar
Ravi.gothwal@hcgel.com	Ph.: +91 98330 90434 / 98211 94418
Tel: +91 95996 55711	Email: anoop@cdr-india.com / suraj@cdr-india.com

Safe Harbor

This document may contain forward-looking statements about Healthcare Global Enterprises Limited and its Subsidiaries, which are based on the beliefs, opinions, and expectations of the company's management as the date of this Investor release and the companies do not assume any obligation to update their forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. Consequently, readers should not place any undue reliance on such forward-looking statements.